[ Magenta Therapeutics raises $50M in Series B ]

Magenta Therapeutics has raised $50 million in Series B funding.

Founded in 2016, Magenta Therapeutics researches, develops and commercializes hematopoietic stem cell transplants for the treatment of immune and blood-based diseases.

The new money  will be used to develop Magenta’s therapies using stem cells and bone marrow transplants.

Funding  Series B
Founded  2016
Country  USA
City  Cambridge, Massachusetts
Founder / CEO  Jason Gardner
Deal Size  $50M
Investors  GV
 Atlas Venture
 Third Rock Ventures
 Partners Innovation Fund
 Access Industries
 Casdin Capital
Previous Investors  Atlas Venture
 Third Rock Ventures

[adyen action=”checkout_button”]